Bernhard Meier, MD

• Professor and Chairman of Cardiology
• Swiss Cardiovascular Center Bern
• University Hospital
• Bern, Switzerland

It is unlawful to prevent pregnant employees from working in occupations that may expose them to radiation hypertension diabetes innopran xl 40 mg order. All pregnant workers should have a specific dosimeter blood pressure bottom number 90 80 mg innopran xl order, to be worn at the waist under the protective garment arrhythmia unspecified icd 9 code innopran xl 40 mg buy amex, issued and read monthly blood pressure monitor cvs cheap 80 mg innopran xl with mastercard. The work related restriction limit for the embryofetus radiation exposure equivalent dose is 0 heart attack untreated purchase 80 mg innopran xl with visa. It should be noted that reference values of 1 mSv are seldom recorded for an entire year in this location [30]. Conclusions pediatric patients Equipment routinely used for pediatric procedures of any kind should be appropriately designed, equipped, and configured for this purpose. Appropriate modifications should be made to accommodate the variable procedural requirements as well as the wide age and weight range of these patients [31,32]. The use of unmodified adult settings for small patients (<40 kG) can result in both unnecessary patient irradiation and substandard image quality. Radiation safety is one of several priorities that must be attended to in the cardiac catheterization laboratory. Establish a radiation safety program for the laboratory, incorporating the physicist for radiation training, equipment purchase, and safe maintenance. Require and document the appropriate radiation safety training both upon employment and with annual updates. Purchase and properly operate imaging equipment with dose limiting capabilities and appropriate dose notification. Mandate the wearing of the dosimetry badge(s) by incorporating badge use as a component of the pre-procedure "time out. Establish followup parameters with policies for those patients receiving high radiation doses. When a radiation conscious environment has been established in the cardiac catheterization laboratory, the patients, staff, and physicians will all benefit. Report 168: Radiation Dose Management for Fluoroscopically Guided Interventional Medical Procedures. Radiation associated lens opacities in catheterization personnel: results of a survey and direct assessments. Interventional cardiologists and risk of radiation induced cataract: results of a French multicenter observational study. Management of patient and staff radiation dose in interventional radiology: current concepts. Quality improvement guidelines for recording patient radiation dose in the medical record for fluoroscopically guided procedures. Occupational radiation doses to operators performing fluoroscopicallyguided procedures. Radiation exposure to the operator performing cardiac angiography with Uarm systems. Occupational health hazards in the interventional laboratory: progress report of the Multispecialty Occupational Health Group. A summary of recommendations for occupational radiation protection in interventional cardiology. Comparing strategies for operator eye protection in the interventional radiology suite. Minimising radiation exposure to physicians performing fluoroscopically guided cardiac catheterisation procedures: a review. Reduction of scatter radiation during transradial percutaneous coronary angiography: a randomized trial using a lead free radiation shield. Pause and pulse: ten steps that help manage radiation dose during pediatric fluoroscopy. Sinclair Keynote Address: effects of childhood radiation exposure: an issue from computed tomography scans to Fukushima. Radiation dose reduction in the invasive cardiovascular laboratory: implementing a culture and philosophy of radiation safety. Clinical determinants of radiation dose in percutaneous coronary interventional procedures: influence of patient size, procedure complexity, and performing physician. The catheterization laboratory and interventional vascular suite of the future: anticipating innovations in design and function. Patient radiation dose audits for fluoroscopically guided interventional procedures. This article discusses the rel evance of cell therapy to interventional cardiology, outlining the progress of over a decade of clinical trials, and looks to future direc tions for clinical research. Subsequent controversies notwithstanding, the papers from the Isner and Anversa groups heralded the beginning of intense activity in cardiovascular therapy which continues to this day. Myocardial regeneration Origin of concept the concept of the adult stem cell was born over 30 years ago, fol lowing the identification of a bone marrow cell capable of reconsti tuting hematopoiesis in irradiated mice [1]. This challenged the previously held belief that the vascularization of adult ischemic tissue was restricted to the proliferation and migra tion of mature endothelial cells. The next key development, and now widely recognized as the landmark paper within the field of cardiovascular cell therapy, was the description by Orlic et al. Further work has shown that stem cells are able to transdifferentiate into Within cardiology, stem cell therapy has generated huge interest by challenging the longheld paradigm of developmental biology that the heart is a terminally differentiated organ, and as such cannot be repaired. Previously, the extent of myocardial necrosis had been shown to be intimately linked to the duration of coronary artery occlusion [13,14]. Such studies were critical in creating the drive forward in reperfusion therapy, but also led clinicians and scientists alike to think of myocardial injury as an irreversible event. Such ideas were called into question with the observation that adult hearts contained large numbers of mitotic figures [15­ 17]. However, the proportion of mitotic cardiomyocytes was extremely small, suggesting they could not function alone as an effective repair system. The possibility that these dividing cells might have arisen from an extracardiac source, such as the bone marrow, was postulated by studies performed in sexmismatched cardiac transplant patients. In males receiving female hearts, cardiac biopsies revealed Ychromosomecarrying cardiomyo cytes [17­19], intimating that cells from an extracardiac source could potentially engraft and differentiate into cardiac tissue. This marked the first recognition that the heart could receive cells from an extracardiac source. To explain this phenomenon, it was suggested that these cells might have arisen from the bone marrow, being released and engrafting either as a lowlevel process of con tinual renewal or in direct response to injury [8,11]. Alternative suggestions included the possibility of a locally resident popula tion of cardiac stem cells, with selfrenewing, multipotent, and clonogenic potential [20]. This occurs in response to the release of cytokines leading to the chemotactic migration of stem and progenitor cells to the area of injury. In addition, the capture of cells at the site of ischemia has been shown to be aided by the upregulation of integrins and intercellular adhesion molecules [27­30], and by the mediation of platelets [31]. For many clinicians, the demonstration of safety alone is insufficient grounds on which to proceed to larger clinical studies. It also supports the idea that no particular cell type should be omitted, and that functional recovery is dependent upon a balance between the various subpopulations present in the mononuclear fraction. Timing of cell delivery the timing of cell delivery is an obvious design difference between trials. However, these observa tions are so far anecdotal and could be explained by methodologic issues such as the release of dye from apoptotic cells in the area of fibrosis or by the use of unfractionated bone marrow, which includes other cell precursor populations. Nonetheless, they are consistent with the basic postulate that stem cells differentiate along milieu dependent pathways. Damaged adult myocardium is devoid of key embryonic growth factors, meaning an inability to recreate the nec essary environment to stimulate myocyte growth or regeneration. This presents a challenge, and accordingly stimulates the search for novel strategies to encourage transplanted cells down the cardiac differentiation pathway prior to transplantation, if not in situ. However, there is debate surrounding the safety of this technique, particularly on the issue of their potential for arrhythmogenesis [34­36]. Countering the idea that stem cells transdifferentiate into functioning cardiomyocytes, Hofmann et al. Furthermore, a study examining the 1 day kinetics of transplanted cells indicated that engraftment is a temporary phenomenon, with myocardial activity dropping off between 2 and 20 hours postintracoronary delivery from ~5% to ~1% [52­54]. This would suggest any positive effects are likely to occur by means other than by direct tissue incorporation. Factors accounting for the transiency of cell retention could be related to a reduced adhesive status of the myocardial microcirculation, and/or the functional performance of delivered cells. Studies are required to investigate this further, and to examine whether pharmacologic manipulation of the microcirculation either at the time of, or prior to , cell delivery makes any difference. Several metaanalyses, utilizing data from published studies, have been produced in recent years. Unfortunately, the results of these are in many ways as disparate as the results of individual studies themselves. The Francis group have raised concerns regarding discrepancies in reporting of cell therapy trials [60]. Given the large number of intended participants compared to previously published studies (both trials and metaanalyses) and the use of mortality as primary endpoint, its results are eagerly awaited. They demonstrated not only that it was procedurally safe, but that it was associated with clinical improvement detectable at 3 months and maintained to 12 months. Notably, there was a demonstrable improvement in regional wall motion at the target site [68]. It should be noted, however, that "con cerns about the integrity of certain data" in the published study have been raised and are being investigated at the time of writing [73]. Both of these groups offer clear advice, and warn against research proceeding without international consensus, aiming to avoid further small, underpowered studies. Conclusions Despite recent technological and pharmacologic advances made within the field of interventional cardiology reducing mortality from coronary artery disease, it continues to cause significant morbidity and efforts have been directed to developing ways of improving endothelial and myocardial function in patients in order to prevent future coronary events. The last two decades have seen an explosion of interest in the use of autologous stem cell therapy to improve the outcome for patients living with coronary heart disease. Although the deliv ery of autologous stem cells to the heart appears to be safe, many unanswered questions remain regarding their mechanism of action, the optimum cell type, method, and timing of delivery. The radiation sensitivity of normal mouse bone marrow cells, determined by quantitative marrow transplantation into irradiated mice. Ischemia and cytokineinduced mobiliza tion of bone marrowderived endothelial progenitor cells for neovascularization. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Neovascularization of ischemic myo cardium by human bonemarrowderived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bonemarrow cells: a pilot study and a randomised controlled trial. Hematopoietic cells from bone marrow have the potential to differentiate into cardiomyocytes in vitro. Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. Bone marrow cells differentiate in cardiac cell lineages after infarction independently of cell fusion. Evidence for cardiomyocyte repopula tion by extracardiac progenitors in transplanted human hearts. Cardiomyocytes of noncardiac origin in myocardial biopsies of human transplanted hearts. Cardiac progenitor cells from adult myocar dium: homing, differentiation, and fusion after infarction. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Stromal cellderived factor1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovasculariza tion. Intercellular adhesion molecule1 is upregulated in ischemic muscle, which mediates trafficking of endothelial progenitor cells. Multistep nature of microvascular recruit ment of ex vivoexpanded embryonic endothelial progenitor cells during tumor angiogenesis. Role of beta2integrins for homing and neovascularization capacity of endothelial progenitor cells. A homing mechanism for bone marrowderived progeni tor cell recruitment to the neovasculature. Platelets secrete stromal cellderived factor 1alpha and recruit bone marrowderived progenitor cells to arterial thrombi in vivo. Marrow stromal cells for cellular cardio myoplasty: feasibility and potential clinical advantages. Autologous skeletal myoblast transplanta tion for severe postinfarction left ventricular dysfunction. Safety and feasibility of autologous myoblast transplantation in patients with ischaemic cardiomyopathy: fouryear followup. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. Transcoronary transplantation of autologous mesenchymal stem cells and endothelial progenitors into infarcted human myocardium. Intracoronary injection of bone marrow derived mononuclear cells early or late after myocardial infarction: effects on global left ventricular function. Bonemarrowderived cells for car diac stem cell therapy: safe or still under scrutiny Oneday kinetics of myocardial engraftment after intracoronary injection of bone marrow mononuclear cells in patients with acute and chronic myocardial infarction.

Ideally arrhythmia upon exertion discount 80 mg innopran xl, this is via the safety wire that was placed at the beginning of the procedure blood pressure quickly lower innopran xl 80 mg order visa. If a safety wire was not placed pulse pressure journal cheap generic innopran xl uk, then it may be necessary to consider wiring across the arteriotomy site from the contralateral femoral access site blood pressure chart different ages buy 80 mg innopran xl with mastercard. Technically blood pressure medication fluid retention buy generic innopran xl, this can range from being relatively simple if the issue is an unacceptable residual stenosis of the largebore access arteriotomy, to exceptionally challenging if there is a complex dissection, perforation, avulsion or significant hemorrhage from the largebore arteriotomy site. Obviously, if any of these more serious complications arise, more advanced salvage techniques such as covered stent placement are required. Valve Academic Research Consortium criteria for major and minor vascular complications are presented in Box 58. Acute reduction in left ventricular afterload can induce development of a dynamic intracavitary gradient, particularly in patients with left ventricular hypertrophy, small chamber size, and any preexisting left ventricular outflow tract obstruction. Arterial pressure recordings can reveal hypotension and new onset of a spikeanddome waveform. Clinical manifestations of acute aortic insufficiency include hypotension, a widened pulse pressure, flash pulmonary edema, cardiovascular collapse and arrest usually with pulseless electrical activity. Left ventricular pressure recordings show a steep rise in left ventricular diastolic pressure, equaling aortic diastolic pressure prior to enddiastole in the setting of severe aortic regurgitation. By contrast aortography, severe aortic insufficiency is evidenced by instantaneous opacification of the left ventricle. Clinical presentation can be insidious as blood gradually accumulates in the pericardium, not becoming clinically manifest as hypotension until several minutes later. Echocardiography confirms the diagnosis of pericardial effusion and can show evidence of tamponade physiology. Treatment is emergent pericardiocentesis and discontinuation of anticoagulation with protamine administration if heparin was Table 58. Depending on the site and size of perforation, bleeding sometimes ceases spontaneously; in other cases, limited cardiac surgery with patch placement is required to obtain hemostasis. Honest, open, patientcentered conversations are mandatory to establish a plan of care tailored to an individual. Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Prevalence and characteristics of unoperated patients with severe aortic stenosis. Transcatheter aorticvalve implantation for aortic stenosis in patients who cannot undergo surgery. Percutaneous transluminal valvuloplasty of acquired aortic stenosis in elderly patients: an alternative to valve replacement Balloon dilatation of calcific aortic stenosis in elderly patients: postmortem, intraoperative, and percutaneous valvuloplasty studies. Percutaneous transluminal balloon valvuloplasty of adult aortic stenosis: report of 92 cases. Changes in left ventricular systolic performance immediately after percutaneous aortic balloon valvuloplasty. The Mansfield Scientific Aortic Valvuloplasty Registry: overview of acute hemodynamic results and procedural complications. Serial left ventricular performance evaluated by cardiac catheterization before, immediately after and at 6 months after balloon aortic valvuloplasty. Early and late changes in left ventricular systolic performance after percutaneous aortic balloon valvuloplasty. Analysis of the early rise in aortic transvalvular gradient after aortic valvuloplasty. Balloon aortic valvuloplasty in adults: failure of procedure to improve longterm survival. Threeyear outcome after balloon aortic valvuloplasty: insights into prognosis of valvular aortic stenosis. Percutaneous balloon valvuloplasty in adult aortic stenosis: a palliative treatment but not without risk. Contemporary use of balloon aortic valvuloplasty in the era of transcatheter aortic valve implantation. Emerging indications, inhospital and long term outcome of balloon aortic valvuloplasty in the transcatheter aortic valve implantation era. Postmortem and intraoperative balloon valvuloplasty of calcific aortic stenosis in elderly patients: mechanisms of successful dilation. Mechanism of reduction of aortic valvular stenosis by percutaneous transluminal balloon valvuloplasty: report of five cases and review of literature. Assessment of left ventricular and aortic valve function after aortic balloon valvuloplasty in adult patients with critical aortic stenosis. Effect of balloon aortic valvuloplasty on the dynamics of left ventricular ejection. Restenosis 3 months after successful percutaneous aortic valvoplasty: a clinicopathological report. Clinical and hemodynamic followup after percutaneous aortic valvuloplasty in the elderly. Aortic balloon valvuloplasty prior to orthotopic liver transplantation: a novel approach to aortic stenosis and endstage liver disease. Balloon aortic valvuloplasty as a bridge to liver transplantation in patients with severe aortic stenosis: a case series. Emergent balloon aortic valvuloplasty as a bridge to transcatheter aortic valve implantation with marked risk reduction of perioperative and postoperative mortality. Indications for cardiac catheterization and intervention in pediatric cardiac disease: a scientific statement from the American Heart Association. Healthrelated quality of life after transcatheter aortic valve replacement in inoperable patients with severe aortic stenosis. Outcome after aortic valve replacement for lowflow/lowgradient aortic stenosis without contractile reserve on dobutamine stress echocardiography. Impact of myocardial fibrosis in patients with symptomatic severe aortic stenosis. Transcatheter aortic valve replacement: outcomes of patients with moderate or severe mitral regurgitation. Interplay between mitral regurgitation and transcatheter aortic valve replacement with the CoreValve Revalving System: a multicenter registry. Prevalence and impact of preoperative moderate/severe tricuspid regurgitation on patients undergoing transcatheter aortic valve replacement. Transcatheter aortic valve implantation for the treatment of severe symptomatic aortic stenosis in patients at very high or prohibitive surgical risk: acute and late outcomes of the multicenter Canadian experience. Evaluation of multidimensional geriatric assessment as a predictor of mortality and cardiovascular events after transcatheter aortic valve implantation. The impact of frailty status on survival after transcatheter aortic valve replacement in older adults with severe aortic stenosis: a singlecenter experience. Results of repeat balloon valvuloplasty for treatment of aortic stenosis in patients aged 59 to 104 years. Cavalaortic access to allow transcatheter aortic valve replacement in otherwise ineligible patients: initial human experience. Complications and Outcome of balloon aortic valvuloplasty in highrisk or inoperable patients. Percutaneous aortic valve replacement: vascular outcomes with a fully percutaneous procedure. Percutaneous endovascular aortic aneurysm repair: a prospective evaluation of safety, efficiency, and risk factors. Ultrasoundassessed plaque occurrence in the carotid and femoral arteries are independent predictors of cardiovascular events in middleaged men during 10 years of followup. Comparison of vascular closure devices for access site closure after transfemoral aortic valve implantation. Iatrogenic pericardial effusion and tamponade in the percutaneous intracardiac intervention era. Anatomy of the aortic valvar complex and its implications for transcatheter implantation of the aortic valve. Aortic root dimensions among patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Aortic annulus and root characteristics in severe aortic stenosis due to bicuspid aortic valve and tricuspid aortic valves: implications for transcatheter aortic valve therapies. Optimizing technique and outcomes in structural heart disease interventions: Rapid pacing during aortic valvuloplasty Impact of rapid ventricular pacing during percutaneous balloon aortic valvuloplasty in patients with critical aortic stenosis: should we be using it Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium. Balloon aortic valvuloplasty in the era of transcatheter aortic valve replacement: acute and longterm outcomes. After the onset of symptoms, severe aortic stenosis is associated with a median survival of approximately 2 years without intervention [2]. Similarly, medical therapy has not been shown to significantly impact the disease pro cess. Therefore, there continued to be a great need for novel thera pies to treat patients without surgical options for aortic valve replacement. For specific patients in whom neither the transfemoral nor traditional chest access approaches are consid ered feasible, operators have successfully implanted the valve using access at the subclavian artery, axillary artery, carotid artery, or femoral vein (via a transseptal or transcaval approach). The lack of appropriate devices for a frequently noncalcified aortic valve and large annulus will need to be resolved before this technique can be widely applied to pure aortic regurgitation cases. Middle row (left and middle): CoreValve images used with permission by Medtronic © 2016. Thus, the heart team approach is absolutely essential to ensure that the best possible options are made available to each individual patient. When the annulus is too small or too large to accommodate a transcatheter device, surgery is sometimes the only option. In practice, most valves that require an 18 Fr sheath can be placed through a minimal luminal diameter of 6 mm, and with the 14 Fr S3 sheath, as low as 5 mm, but individual practices differ. The annulus is rarely a circular structure but frequently elliptical, so valve sizing based on single diameter echocardiographic measurements can lead to significant error. Tomographic assessment of the aortic root is also important to evaluate the dis tance between the annulus and the coronary artery ostia. The required iliofemoral diameter is dependent on the type and size of valve that is used. The decision regarding adequate iliofemoral access is comprehensive and must take into account not only the size of the artery, but the presence of calcification, whether the calcification is circumferential, and the presence of significant tortuosity. Calcific arteries are less compli ant and pose a higher risk for vascular complications, especially when the luminal diameter is borderline and calcification is cir cumferential [16]. A closure device is then used to repair the arteriovenous fistula that is created at the conclusion of the procedure. This is more common with selfexpanding valves, but irrelevant in patients who are already pacemaker dependent. However, chronic occlusions, especially those with adequate collateral flow, are permissible to be approached less aggressively, but each case must be considered individually. There can be considerable variation from institution to institution with regard to the facilities, personnel, and equipment that are involved in the procedure. Additionally, at most institutions the procedure is performed with the active participation of both interventional cardiologists and cardiac surgeons for similar reasons. As a result, many institutions have transitioned to performing selected procedures under conscious sedation with excellent results [27,28]. Once the patient is prepared and appropriate seda tion administered, the next step is to obtain vascular access for the procedure. This should be on the side with the most favorable anatomy as determined by preop evaluation. In this example, the femoral artery bifurcation is much higher than usual, above the midfemoral head. The initial arteriotomy was found to be incorrectly placed in the superficial femoral artery (a). The micropuncture sheath was therefore removed and access reattempted under fluoroscopy with image overlay (b). Correct placement is achieved and confirmed to be located above the bifurcation and below the inferior epigastric artery (c). Alternatively, using ultrasound guidance to identify the bifurcation can also be very useful. Once the correct arteriotomy location is confirmed, the micropuncture sheath is exchanged for a short 5 Fr sheath. Contralateral arterial access is obtained in a similar manner, and this sheath is used to place a 5 Fr pigtail catheter in the aortic root for angiography during valve position/deployment. While this can instead be placed from a radial approach, we prefer the femoral arterial access so that endovascular repair of any delivery sheath complications can be accomplished. Venous access is obtained with a sheath large enough to accommodate a temporary pacemaker wire. If desired, a second venous access can be used for a pulmonary artery (Swan­Ganz) catheter, although this is usually performed from the neck if necessary. This stepwise process requires the replacement of the wire to hold arterial position during each sheath and Perclose exchange. The Perclose strings are then pulled gently away and secured with a clamp on the adjacent drape, taking care not to lock the knot. The use of preclosure devices has reduced the need for surgical cutdown and primary repair in the vast majority of cases [29,30].

Generic 40 mg innopran xl with amex. iHealth Air Wireless Pulse Oximeter.

Computed tomography as a tool for percutaneous coronary intervention of chronic total occlusions blood pressure remedies innopran xl 80 mg order on-line. They were very bulky blood pressure medication that starts with c purchase innopran xl amex, difficult to position as there was no guidewire lumen blood pressure medication insomnia buy 40 mg innopran xl with visa, and too compliant to safely expand resistant lesions in coronary arteries blood pressure higher in one arm purchase innopran xl in united states online. Further understanding and development in manufacturing techniques and evolution of materials have reduced the profile of angioplasty balloons while increasing their robustness blood pressure medication nerve damage generic innopran xl 80 mg without prescription, deliverabil ity, reliability, and safety profile. Similarly, workhorse guidewires have been developed with improvements in torque and force trans mission while having more durable and less traumatic but shape able tips. Specialty guidewires have been developed for the treatment of specific lesion types including chronic total occlusions. A wide range of guide catheters, guidewires, and angioplasty balloons are now available, and continue to evolve to overcome variations in anatomy, changes in vascular access, and evolution in technique. The appropriate selection and safe and optimal use of these devices can reduce procedural time and increase procedural success and safety with hopes of improving clinical outcomes. The optimal view for left and right coronary intubation is the left anterior oblique because in most patients it offers the least superimposition of the coronary ostia with the left and right aortic sinuses. Size requirements the advantages and disadvantages of smaller and larger catheter sizes are listed in Table 5. Routine angioplasty using 5 French (Fr) guid ing catheters may be ideal when direct stenting is planned, but not all stents are deliverable through a 5 Fr guide and most bifurcation tech niques are not applicable [1]. For bifurcation techniques requiring the simultaneous insertion of two stents (Crush, V stenting), 7 Fr (2. The use of guide catheters greater than 8 Fr is extremely rare in contemporary coronary intervention. Shape relection Selection of guide catheter shape is critical to allow positioning of the catheter coaxially with the proximal segment of the artery, to reduce the risk of catheterinduced vessel trauma, and optimize support during intervention. When selecting the shape of the cath eter, the following factors should be considered: the curve and fit of the diagnostic catheter; size of the aortic root; origin and take off of the artery; location and complexity of the lesion; and the devices likely to be utilized during intervention. Guide catheter selection Functional design of modern guide catheters Guide catheters permit safe intubation of the coronary ostia, accurate hemodynamic monitoring, injection of contrast, and passage of guide wires, balloons, and stents. The clinical, anatomic, and angiographic scenario must be considered when selecting the size, shape, and length of a guide catheter. Modern catheters have a soft tip to reduce the risk of vessel trauma during intubation or manipulation. The wall consists of an outer layer which retains a predefined curve and increases shaft stiffness to provide backup support during intervention, a middle layer of wire braid to increase kink resistance, improve torque transmission, and shaft radiopacity, and a smooth lubricated inner layer to facilitate the transit of equipment. Guide catheters have thinner walls than diag nostic catheters to increase inner lumen size and can be easily damaged by excessive rotation (Table 5. When difficulty is encountered in engaging the coronary ostia, one must first consider whether the guide catheter shape is appro priate. The curve sizes of different shapes have been largely standardized and the comparable curve sizes used most commonly are shown in Table 5. Outer lumen size (French) Guide/manufacturer Launcher/Medtronic Vista Brite Tip/Cordis Mach1/Boston Scientific Viking/Guidant Abbott Wiseguide/Boston Scientific Inner lumen (in) 5 0. Techiques to obtain support other than the passive support allowed by the guide catheter shape are discussed later in this chapter. The take off of the right coronary artery tends to vary more than that of the left coronary. Occasionally, shorter lengths (85 or 90 cm) are required to reach for distal lesions. Longer lengths (110­115 cm) are required for unusually tall patients or severely tortuous aortoiliac vessels. The use of a long sheath and of longer balloon catheters (>145 cm) has partially overcome this problem but stent delivery catheters remain 135 cm. Side holes help to maintain coronary perfusion when there is the likelihood of ostial obstruction by the guide catheter that results in pressure dampening. This can occur when using a larger guide caliber, in the presence of aortoostial disease, noncoaxial engage ment, and in small caliber arteries encountered in smaller patients. Side holes can reduce contrast opacification of the arteries with a consequent reduction in image quality and increased overall con trast dye utilization. The shape of the guide catheter is an important component of the backup or support system that allows delivery of devices to the target lesion. Changing the guide catheter to improve support in the middle of a procedure can be problematic, and therefore careful consideration of guide support prior to intervention is critical. It is also important to appreciate that selection of a guide with optimal backup may obviate the need for stiffer wires or bal loons, with a corresponding reduction in cost and procedure time. Variation in access site the same guide catheters can be used for transradial access as well as transfemoral access. Dedicated transradial guide catheters include the Barbeau, Ikari, and brachial/radial curves. Support Complex anatomic situations including tortuosity, calcification, or diffuse atherosclerosis frequently require escalating degrees of backup support. The components of the "backup" support intrinsic to an angioplasty system includes the guide catheter, guidewire(s), and balloon(s) in the target artery. The components can be changed individually or in combination as demanded by the difficulties that are encountered. Hybrid strategies using more complex wire and/or balloonbased techniques are sometimes required to overcome more challenging anatomy. This technique is also referred to as active engagement or "deep seating" of the guide cath eter. The risk of damage to the artery can be minimized by ensuring that the catheter is advanced coaxially over a balloon already inside the vessel. Stabilization of the system while advancing the guide catheter is sometimes required and can be achieved by inflating a balloon within the artery. When considering the use of active sup port, it is important to bear in mind that deep engagement of large arteries can cause profound ischemia. The use of side holes may not prevent and may even delay detection of catheterinduced ischemia. A further risk is that of air embolism following aspiration through the Yconnector while the back pressure in the guide catheter is reduced as a result of damping inside the artery. Despite these risks, Wire support the buddy wire technique refers to the passage of a second or third guidewire distal to a target lesion to provide additional support for delivery of angioplasty equipment. This is a commonly used strategy for crossing difficult lesions with a balloon or a stent [7]. The additional wire provides a rail that facilitates advancement across calcification, tortuosity, or recently deployed stents. The wire facilitates active engagement of the guide catheter and can straighten tortuosity when a supportive wire is used. This tech nique is also the first essential step for the distal anchor balloon technique. The use of stiff hydrophilic wires as a "buddy wire" is discouraged because of the risk of perforation. Occasionally, if support from the guide and an additional wire still proves insufficient, additional techniques are needed and are delineated subsequently. Low inflation pressures are essential to reduce the risk of dissection or damage to a small right ventricular branch or diagonal/marginal branch. In these branches, ischemia resulting from prolonged infla tion is well tolerated. The balloon is positioned distal to the lesion and inflated at low pressure allowing enough space for the stent to be fully advanced across the target stenosis. It is impera tive to remember that the distal anchoring balloon must be deflated and removed before the stent is deployed. In addition to providing extra support, the shaft of the distal balloon also acts as a rail to facilitate stent advancement. The operator needs to be experienced enough to anticipate when the force required may detach the stent from the balloon. Compatibility of different guide catheter lengths and diameter is a limiting factor. Mainly a 6 Fr, 110 cm long "child" guide catheter is combined within an 85 or 90 cm 7 or 8 Fr "mother" guide catheter. A greater difference between the lengths of the "mother" and "child" catheters, however, enables more flexibility because it permits further advancement of the "child" catheter into the artery. The "mother" catheter shape is selected to cannulate the ostium of the tar get vessel and is inserted first. In contrast, a straight "child" catheter, with a soft atraumatic tip, is desirable. If an unusual shape is required for the "mother" catheter that is not available in a short length, the solution is to cut the distal end of a 100 cm guiding catheter of the selected shape and insert within it a smaller valved sheath. Leakage from an insufficiently tight seal can affect the quality of contrast injec tions. A further risk is the potential for air trapping within the sheath and subsequent inadvertent intracoronary air embolism. It may also be useful for example when a 7 or 8 Fr guide is too large to engage ostial disease or a critically diseased vessel and other situations where deep engagement of the guide is undesirable. The smaller guide can then be engaged into the vessel ostium, whereas the larger guide adds passive backup to the system. Relative adjustments of the positions of the two guide tips can help to achieve optimal orientation of the tip of the "daughter" catheter. This system uses the target vessel itself to provide the extra backup support required for stent delivery. Furthermore, the absence of a primary curve and the flexibility of its tip permit the "child" catheter to remain coaxial with the target vessel, thereby minimizing the risk of catheterinduced coronary dissection. However, its use requires removal of the Yconnector, making the procedure more demanding [11]. The back stream prevention valve (Terumo) is connected to the guide catheter of 6 or 7 Fr. The conventional Yconnector is attached to Kiwami (child) which was inserted in the 6 or 7 Fr (mother) catheter. Because the effective length of Kiwami is 120 cm, the projected length from the mother catheter differs depending on the length of mother cathe ter used [12]. The GuideLiner catheter is a coaxial device mimicking the "mother­child" technique. The device is mounted on a monorail system, which extends the guide catheter and enables deep intubation of the coronary artery to achieve extra support and improve coaxial alignment. It has a distal end of 20 cm, consisting of a flexible extension with a radiopaque marker situated 2. Furthermore, rapid exchange helps with deployment through the existing hemostatic valve without extending the guiding catheter length, and so does not limit the useable length of balloons and wires. Morever, they found a device and procedural success rate of 93% and 91%, respectively, without major complications and a small incidence of minor com plications (3%). The safety and efficacy of utilizing the GuideLiner monorail catheter to treat complex lesions was confirmed in a recent experience published by Chang et al. On the basis of the presented data, the authors suggested the following tips and tricks for a safe and effective use of this device: · In case of noncoaxial alignment of the coronary ostium and extreme proximal vessel tortuosity. This problem was solved, in the last verison of the device GuideLiner catheter (V2), by replacing the metal transition zone with a lubricious polymer. The device is mounted on a monorail system, which extends the guide catheter and enables deep intubation of the coronary artery. It is made of a distal end of 25 cm covered by a hydrophilic polymer, joined to a 120cm compact metal hypotube. The distal flexible extension consists of a pair radiopaque markers, the first situated 2 mm from the tip and the second 3 mm from the transition collar. Guidewires are required to cross the target lesion and to provide support for the delivery of balloons, stents, and other devices while at the same time minimizing the risk of vessel trauma. There is no single wire that has the perfect combination of these characteristics for all situations. Wire selection depends on which characteristics are thought to optimally facilitate angioplasty for a given clinical and angiographic scenario. Using stainless steel as the core material improves the steerability and torque control, but steel wires can be deformed by tortuosity and cannot be reshaped. A nitinol core also offers excellent torque control, but the wire will retain its shape and can be reshaped if deformed. Guidewires can be classified into general purpose or "workhorse" and dedicated wires (Table 5. Workhorse guidewires typically possess soft tips, but the amount of shaft support varies (Table 5. Although some wires have preshaped tips, the tip stiffness can be increased by heating during the preshaping process so the angle may not match the anatomy. Guidewire shaping can be achieved in many ways including curling the shaping ribbon of the wire over the side of the introducer needle, advancing the wire through the introducer tip and bending it gently outside of the introducer needle tip, or curling it with a finger. It does not matter which method is used to ed shape the wire tip, provided that it is done without damaging the wire. Hydrophilic wires are not recommended as a first choice for general purpose use, because the highly lubricious tip can easily slip beneath a plaque and create a dissection during insertion. These wires also have a higher tendency to migrate distally and increase the risk of perforation, give less tactile feedback, and have lower visibility. Highly tortuous vessels require a flexible lubricious wire in the first instance. The characteristics of guidewires can be altered by modifying specific components during the production process. The handling characteristics of different wires vary substan tially and even the same wire can have a very different "feel" under different circumstances. For example, wires frequently perform differently and offer different tactile feedback in more complex lesion subsets including those with diffuse disease with heavy calcification or angulation.

Patients with aortic paravalvular regurgitation can present with a diastolic decre scendo murmur over the left sternal border wellbutrin xl arrhythmia purchase 80 mg innopran xl with amex, and patients with mitral paravalvular regurgitation often present with a pansystolic murmur over the mitral area with radiation incumbent on the direction of the major jet blood pressure medication hair growth 40 mg innopran xl buy with amex. Laboratory findings Diagnostic evaluation Basic laboratory testing should be performed to assess presence pulse pressure less than 10 innopran xl 80 mg buy fast delivery, severity blood pressure 400 purchase 40 mg innopran xl free shipping, and mechanism of anemia including markers of hemolysis blood pressure chart who generic 40 mg innopran xl with amex. These should include hemoglobin, hematocrit, reticulocyte count, mean corpuscular volume, reticulocyte count, haptoglobin, lactate dehydrogenase, iron, folic acid, total and direct bilirubin, and peripheral smear examination for the presence of schistocytes. The following findings typically suggest hemolysis: undetectable hapto globin level, lactate dehydrogenase >500 units, >1% schistocytes on peripheral smear, and >5% reticulocytes. While ante rior aortic paravalvular regurgitation is easily detected using this modality, detection of posterior leaks is often hampered because of acoustic shadowing from prosthetic valves. Furthermore, the phe nomenon of "gardenhosing," which is caused when a strong color flow Doppler signal emanates from a small defect and fans out to occupy a relatively small left ventricular outflow tract, makes accu rate assessment of the severity of the paravalvular regurgitation by color flow difficult. Intracardiac imaging, although not commonly used, can assist with procedural imaging, especially pos teriorly located aortic paravalvular regurgitation which can be imaged using an intracardiac imaging catheter positioned in the Interventional Cardiology: Principles and Practice, Second Edition. Aortography can allow accurate assessment of the severity of aortic paravalvular regurgitation in the absence of intravalvular regurgitation. Localization Aortic paravalvular regurgitation is typically localized using the transthoracic aortic short axis view and identifying the regurgita tion in relation to one of six sectors each equaling 60°, based on position on the valve leaflets. In our practice, mitral paravalvular regurgitation localization is performed using a triangulation system utilizing the following landmarks: the anteriorly located aortic valve, the anterolaterally located left atrial appendage, and the medially located atrial sep tum. Others recommend using a clock face system to localize the paravalvular regurgitation. These nomenclature systems allow accurate and effective com munication between the echocardiographer and structuralist, which is essential to the success of transcatheter paravalvular leak occlusion. Transcatheter paravalvular regurgitation occlusion With any device, extreme care must be taken to avoid interference with prosthetic valve leaflet motion or interaction with surround ing structures prior to device deployment. The common indica tions for transcatheter paravalvular regurgitation occlusion include: 1 Clinically and/or hemodynamically significant paravalvular regurgitation as evidenced by symptoms and signs of congestive heart failure or hemolytic anemia; 2 Stable prosthetic valve function; and 3 Defect size involving less than onequarter valve circumference. Contraindications include active infection or endocarditis, and unstable prosthesis and regurgitation involving more than one third of the circumference of the prosthetic annulus. We recommend approaching aortic paravalvular defects using a retrograde aortic approach. We utilize a "5in6" telescoping, coaxial catheter system (125 cm 5 Fr multipurpose diagnostic coronary catheter inside a 6 Fr 100 cm multipurpose guiding catheter) and a 0. Once the defect is cannulated the 5 Fr multipur pose catheter is used to cross the defect followed by the 6 Fr multi purpose guide. Alternatively, the stiff angled glide wire can be extruded out through the native/bioprosthetic aortic valve and snared in the ascending aorta to be exteriorized via the contralateral femoral artery forming a stable arterioarterial rail (modified anchor wire technique). Care must be taken to closely monitor hemodynamics while using this technique, because hemodynami cally significant aortic regurgitation can develop secondary to the rail. For smaller defects necessitating deployment of a single closure device this may not be required; however, for planned deployment of multiple devices either an anchor wire or formation of a rail becomes necessary. Once the anchor wire or arterioarterial rail is in place the guiding catheter can be replaced with a 90 cm Cook Flexor Shuttle sheath to facilitate device delivery. Knowledge of the compatibility of combinations of catheters, wires, and closure devices is crucial to ensure success. This might occur in the case of medial defects, which can be challenging to cannulate because of proximity to the interatrial septum. For medial defects a poste rior location of interatrial puncture with the superior­inferior plane at the level of the defect is recommended as this provides the ability to maneuver catheters toward the defect along the mitral annular plane. Meticulous care is required to maintain an activated clotting time >300 s to avoid development of thrombosis. Top right, bottom left: right anterior oblique and left anterior oblique views of nested Amplatzer vascular plugs with anchor wire in place. Bottom right: Amplatzer vascular plugs ready for deployment, yet still attached to their delivery cables. Top left: Agilis catheter with telescoping catheters, and a still angled Glide wire cannulated through a mitral paravalvular defect. Top right: arrow demonstrates the modified anchor wire technique (arteriovenous loop). Bottom left: an Amplatzer vascular plug being deployed with arteriovenous loop in place. Depending on the size of the defect one or more devices are required, and can be deployed as described in the subsequent sections. An attractive aspect of this technique is the ability to reverse course and remove all devices at the very end of the procedure. Sequential deployment technique using the Anchor wire Simultaneous deployment technique (double wire technique) An 0. Once the first closure device has been successfully deployed, the Shuttle sheath is removed over the guidewire and then reloaded on to the guidewire, leaving the device cable outside of the sheath to facilitate delivery of additional devices using the same sequence. The guiding catheter is removed over the guidewires and two separate 5in6 catheter sys tems are loaded on the guidewires and advanced into the ventricle. The 5 Fr diagnostic catheters are then removed and the 6 Fr guides are used to deploy devices simultaneously. Followup We recommend close followup of the patient to monitor resolution of hemolysis and/or heart failure symptoms. No additional anti platelet or anticoagulation therapy is necessary from the standpoint of the occluder device(s) placed. With the arteriovenous guidewire rail in position, the first closure device can be placed through the shuttle sheath alongside the existing exteriorized guidewire rail. The Shuttle sheath is then removed and reloaded over the arteriovenous rail, leaving the device delivery cable outside the sheath. While surgical closure is considered the gold standard treatment, it may be associated with morbidity and mortality, prompting development of less invasive percutaneous transcatheter techniques. Devices are secured to a delivery cable and inserted into a delivery sheath rang ing 6­10 Fr in size. Device sizes are selected based on twodimen sional echocardiographic measurements; generally the waist of the device should be 1­2 mm larger than the defect size (Table 57. Longer waist lengths are required as interventricular septum thick ness increases, for instance in adults. Preprocedural antibiotic prophylaxis (typically, intravenous cefazolin) is administered as well as aspirin (325 mg) and intrave nous heparin (100 U/kg). Femoral access is usually preferred for defects in the more superior portion of the septum. A balloontipped endhole catheter is then used to cross the tricuspid valve from the right side with the balloon inflated, in order to avoid entrapment of the chordal apparatus during later placement of the device. The glide wire is then snared and exteriorized through the venous access site, establishing an arteriovenous rail. The delivery catheter is then drawn back into the right ventricle until the leftsided umbrella is against the septum, as guided by fluoroscopic and echocardio graphic imaging. Finally, the rightsided umbrella is released by withdrawing the sheath, thus covering the defect. The device is then tested for stability by gentle pulling and pushing under fluoroscopic and echocardiographic guidance. Doppler colorflow is used to determine the presence and degree of residual shunting as well as potential interference with surrounding structures such as the tri cuspid and aortic valves. Once device position is determined to be stable and there is a significant reduction in shunt (mild residual shunt), the device is released. Top right: an arteriovenous rail from femoral artery to internal jugular vein is established. Efficacy and complications Procedural success rates for transcatheter closure are approximately 90­95% for congenital and postsurgical perimembranous and mus cular defects. Residual shunting is usually trivial or mild in degree, with <1% of patients hav ing severe residual shunt requiring surgery [13]. Complications have been reported in up to 10% of patients, including 3­4% risk of rhythm and conduction disturbances, <1% risk of device embolism, <1% risk of major vascular complications, <1% of infection, development of new aortic or tricuspid regurgitation (3­6% of patients, usual of triv ial or mild degree), hypotension, and blood loss [13,14]. Closure performed in the acute setting is associated with a signifi cantly less successful longer term result. While initial procedural suc cess can be as high as 86% [15], the procedural complication rate is 41% including major residual shunting, left ventricular rupture, and device embolization. When cardiogenic shock is present at baseline, despite an 80% procedural success rate, longterm mortality is 93%, reflecting the extreme critical illness present in this population. Prevalence and clinical significance of inciden tal paraprosthetic valvar regurgitation: a prospective study using transoesophageal echocardiography. Outcomes 15 years after valve replacement with a mechanical versus a biopros thetic valve: final report of the Veterans Affairs randomized trial. Paravalvular leakage after mitral valve replace ment: improved longterm survival with aggressive surgery Aortic regurgitation index defines severity of periprosthetic regurgitation and predicts outcome in patients after transcatheter aortic valve implantation. Reoperation for aortic valve periprosthetic leakage: identification of patients at risk and results of operation. Early complications and immediate postoperative outcomes of paravalvular leaks after valve replacement surgery. Natural history of early aortic paraprosthetic regurgitation: a fiveyear followup. Percutaneous repair of paravalvular prosthetic regurgitation: acute and 30day outcomes in 115 patients. Transcatheter closure of congenital ventricu lar septal defects: results of the European Registry. Immediate primary transcatheter closure of postinfarction ventricular septal defects. Common reasons for this gap included advanced age, comorbidities, high operative risk, perceived lack of symptoms, and refusal by patients or family members [7]. The technique found particular application among patients who were too ill to undergo surgery [14]. With a minimally invasive approach, it was possible to achieve immediate reduction in the transvalvular aortic gradient, increase in calculated aortic valve area, and often improvement in left ventricular function [15­17]. Enthusiasm for these acute benefits and accompanying symptom relief [18] was tempered, however, by recognition of their lack of durability. For each element, there exist specialized equipment, essential technique, and opportunities for failure and complications. Inflation and deflation of a noncompliant balloon placed properly across the stenosed aortic valve produces an immediate increase in valvular effective orifice area via three major mechanisms: fracture of calcium deposits, rupture of commissural fusion, and, to a lesser degree, stretch of valve and annular tissue [13,30­32]. This increase in effective orifice area, typically 50% above baseline upon immediate reassessment [33], confers an acute reduction in transvalvular pressure gradient and left ventricular afterload. Correction of afterload mismatch [34] can be associated with an increase in calculated cardiac output and improvement in left ventricular ejection fraction, particularly among those with left ventricular systolic dysfunction at baseline [17,33]. In the absence of a change in stroke volume, improvement in left ventricular performance can be evident in a decrease in ejection time, particularly in the later decelerative phase of systole [35]. This rebound in pressure gradient can be explained in part by a small but measurable increase in stroke volume via reduction in afterload mismatch. Inflammation and fibrosis of the valve following traumatic injury mediate a structural remodeling response that also contributes to restenosis. By 2 months, microfractures persist but with a transition in associated inflammation to a heavier infiltrate of lymphocytes, plasma cells, granulation, and mesenchymal tissue [38]. In the months that follow, the acute inflammatory response gives way to mesenchymal cell proliferation, hyalinization, myxoid change, and dystrophic calcification and scarring [39]. By 6 months, approximately half of patients experience restenosis back to their baseline level of valvular stenosis [18,40,41]. High quality evidence for this approach is lacking and current guidelines do not endorse it [42]. An anterograde approach, in which the balloon approaches the valve via the left ventricle, can be accomplished either via left ventricular apical access or via venous access with accompanying transseptal or caval­aortic [63] puncture. The major advantage of an anterograde approach is avoidance of the arterial system, which is affected by a substantial and sometimes prohibitive burden of atherosclerosis in many candidates (Table 58. Transvenous access, in particular, offers the putative advantage of reduced access site bleeding and vascular complications in association with large bore vascular access. In this approach, access is obtained via a large artery (typically, the common femoral artery), and equipment is advanced over guidewires to the left heart via retrograde passage through the aorta. Challenges particular to the transfemoral retrograde approach include risks of vascular complications, bleeding, often tortuous aortoiliac anatomy, and a long distance from the access point to the aortic valve (70­100 cm), creating opportunities for wire bias, slack, and noncoaxial device positioning across the aortic valve [65]. Indeed, there are numerous other indications for largebore percutaneous arterial access in the modern catheterization laboratory, such as left ventricular hemodynamic support devices [72,73]. The femoral and iliac arteries are commonly affected by atherosclerosis, as shown in Table 58. Selected recent recommendations for this imaging from the Society for Cardiovascular Computed Tomography [76] are presented in Box 58. Attention should be paid in these cases to iliofemoral angiography performed in the context of cardiac catheterization. Special note should be made of the location of the common femoral bifurcation, particular areas of heavy plaque or calcification, anomalies and anatomic variants, and any evidence of vascular injury or soft tissue pathology secondary to prior procedures. Based on these observations, the operator should form a strategy for the laterality, precise craniocaudal position, and caliber of the femoral arteriotomy. As mentioned, there are three principal factors to consider in terms of suitability of vascular access for largebore sheath insertion: minimum diameter, tortuosity, and degree of calcification.

References

• Salama AD, Dougan T, Levy JB, et al. Goodpasture's disease in the absence of circulating anti-glomerular basement membrane antibodies as detected by standard techniques. Am J Kidney Dis 2002;39(6):1162-7.
• Dumont, L., Mattys, M., Mardirosoff, C. et al. Changes in pulmonary mechanics during laparoscopic gastroplasty in morbidly obese patients. Acta Anaesthesiol Scand 1997;41:408-413.
• Wallace MB, Hawes RH, Sahai AV, et al: Dilation of malignant esophageal stenosis to allow EUS guided fine-needle aspiration: Safety and effect on patient management. Gastrointest Endosc 51:309, 2000.
• Lv LQ, Hou LJ, Yu MK, Qi XQ, Chen HR, Chen JX, et al. 'Prognostic influence and magnetic resonance imaging findings in paroxysmal sympathetic hyperactivity after severe traumatic brain injury. J Neurotrauma. 2010;27(11):1945-50.
• Barentsz JO, Richenberg J: European society of urogenital radiology. ESUR prostate MR guidelines 2012, Eur Radiol 22(4):746-757, 2012.
• Obara T, Fujimoto Y, Kanaji Y, et al. Flow cytometric DNA analysis of parathyroid tumors. Implication of aneuploidy for pathologic and biologic classification. Cancer 1990;66(7):1555-1562.